// App-Quantinova.ai

: Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients With Partial-Onset Seizures (POS), With/Without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of Phase III Study 342 (FREEDOM)

Researchers

Presenter

  • Ryan Edbert Husni

Principal Investigators

  • Leock Y Ngo

  • Anna Patten

  • Hidetaka Hiramatsu

  • Kazuaki Watanabe

  • Hirofumi Senokuchi

  • Takamichi Yamamoto

Medical Centers

  • Eisai Co. Ltd. Bunkyo, Tokyo, Japan

  • Eisai Inc, Woodcliff Lake, NJ

  • Eisai Ltd., Hatfield, Hertfordshire, UK

  • Seirei Mikatahara General Hospital, Hamamatsu, Japan

Locations

  • Japan

  • United States

  • United Kingdom

Companies

  • Eisai Co., Ltd.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Epilepsy

Biomarkers

  • Fibrillin-1

Drug/Treatment

  • Perampanel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved